A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer

Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Zhihao LuLin Shen

Abstract

We compared efficacy and safety of paclitaxel/capecitabine therapy followed by capecitabine for maintenance (PACX) versus cisplatin/capecitabine therapy (XP) in advanced gastric cancer. Multicenter, randomized, phase III trial was conducted in China (December 2009-February 2014). Adults (n = 320) with histologically confirmed, untreated metastatic/unresectable gastric or gastroesophageal junction adenocarcinoma; with ≥ 1 measureable lesions according to Response Evaluation Criteria in Solid Tumors 1.0 criteria; Karnofsky performance score ≥ 70 and life expectancy ≥ 3 months were randomized (1:1) to PACX or XP. PACX group received paclitaxel 80 mg/m2 intravenous on days 1 and 8; capecitabine 1000 mg/m2 orally BD on days 1-14, followed by a 7-day rest interval for 4 cycles, followed by maintenance capecitabine at same dosage/schedule until disease progression, unendurable adverse events or death. XP group received cisplatin intravenous 80 mg/m2 on day 1 and capecitabine at same dosage/schedule as PACX group per cycle for 6 cycles. Median progression-free survival (5.0 versus 5.3 months; hazard ratio [95% CI]: 0.906; 0.706-1.164; p = 0.44) and overall survival (12.5 versus 11.8 months; hazard ratio: 0.878 [0.685-1.125]; p = 0.30) ...Continue Reading

References

Feb 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusR Heuman
Nov 18, 2000·Investigational New Drugs·H Ishitsuka
Apr 17, 2003·Oncology·Wasaburo KoizumiUNKNOWN Clinical Study Group of Capecitabine
Jan 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Jan 24, 2006·Anti-cancer Drugs·Junichi SakamotoUNKNOWN Clinical Study Group of Capecitabine
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna D WagnerWolfgang E Fleig
Jan 21, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y-K KangP I McCloud
Jun 30, 2009·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Junichi SakamotoYasuhiro Kodera
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Oct 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T WaddellUNKNOWN European Society of Radiotherapy and Oncology (ESTRO)

❮ Previous
Next ❯

Citations

Jun 30, 2019·Journal of the National Cancer Institute·Jessy Joy van KleefHanneke W M van Laarhoven
Jun 21, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Y YaoF Kong
Dec 23, 2020·Expert Review of Anticancer Therapy·Hossameldin Attia, Elizabeth Smyth
Jan 14, 2021·World Journal of Gastrointestinal Surgery·Yu ZhangMin-Feng Ye

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01015339

Software Mentioned

SAS

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.